Phaseline

Targets › LYZ

LYZ (Lysozyme C): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 3, 1 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2026.

Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents. (UniProt, P61626)

Open in Phaseline: the race on LYZ, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonLactoferrin
Combination of iron-binding glycoprotein and antimicrobial enzyme for enhanced intestinal
LTF, LYZPhase 3DiarrheaDec 2026
City of Hope Medical CenterHuman Lysozyme Goat Milk
Recombinant human lysozyme in goat milk - antimicrobial enzyme that promotes beneficial gu
LYZPhase 1Allogeneic Hematopoietic Stem Cell Transplant Recipient–

Conditions

Diarrhea (3) Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1) University of Washington (1)

Related targets

LTF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.